LEADER 03535nam  2200637Ia 450 
001 9910785914603321
005 20230801225231.0
010   $a0-309-25318-7
010   $a1-283-63636-0
010   $a0-309-25316-0
035   $a(CKB)2670000000275075
035   $a(EBL)3379028
035   $a(SSID)ssj0000665821
035   $a(PQKBManifestationID)11396035
035   $a(PQKBTitleCode)TC0000665821
035   $a(PQKBWorkID)10646588
035   $a(PQKB)10153786
035   $a(Au-PeEL)EBL3379028
035   $a(CaPaEBR)ebr10606369
035   $a(CaONFJC)MIL394882
035   $a(OCoLC)902942425
035   $a(MiAaPQ)EBC3379028
035   $a(EXLCZ)992670000000275075
100   $a20111220d2012      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aEnvisioning a transformed clinical trials enterprise in the United States$b[electronic resource] $eestablishing an agenda for 2020: workshop summary /$fNeil Weisfeld, Rebecca A. English, and Anne B. Claiborne, rapporteurs; Forum on Drug Discovery, Development, and Translation; Board on Health Sciences Policy
210   $aWashington $cNational Academies Press$d2012
215   $a1 online resource (232 p.)
300   $aDescription based upon print version of record.
311   $a0-309-25315-2 
320   $aIncludes bibliographical references.
327   $a""Front Matter""; ""Reviewers""; ""Contents""; ""Tables, Figures, and Boxes""; ""Acronyms""; ""1 Introduction""; ""2 Integrating Community Practice and Clinical Trials""; ""3 Improving Public Participation in Clinical Trials""; ""4 Creating a New Business Model for Clinical Trials""; ""5 Building an Infrastructure to Support Clinical Trials""; ""6 Suggesting an Agenda for Transforming Elements of the Clinical Trials Enterprise""; ""References""; ""Appendix A: Workshop Agenda""; ""Appendix B: Participant Biographies""; ""Appendix C: Registered Workshop Attendees""
327   $a""Appendix D: Discussion Paper: The Clinical Trials Enterprise in the United States: A Call for Disruptive Innovation""""Appendix E: Discussion Paper: Developing a Robust Clinical Trials Workforce""; ""Appendix F: Discussion Paper: Transforming the Economics of Clinical Trials""; ""Appendix G: Discussion Paper: Developing a Clinical Trials Infrastructure""; ""Appendix H: Discussion Paper: Canadian Strategy on Patient-Oriented Research""; ""Appendix I: Discussion Paper: Health Research as a Public Good""; ""Appendix J: Discussion Paper: Novel Ways to Get Good Trial Data: The UK Experience""
327   $a""Appendix K: IOM Staff Paper: Context and Glossary of Select Terms Associated with the Clinical Trials Enterprise""
606   $aClinical trials$zUnited States
606   $aClinical medicine$xResearch$zUnited States
615  0$aClinical trials
615  0$aClinical medicine$xResearch
676   $a615.50724
701   $aWeisfeld$b Neil E$01534649
701   $aEnglish$b Rebecca A$01471734
701   $aClaiborne$b Anne B$01471735
712 02$aInstitute of Medicine (U.S.).$bForum on Drug Discovery, Development, and Translation.
712 02$aInstitute of Medicine (U.S.).$bBoard on Health Sciences Policy.
712 02$aNational Academies Press (U.S.)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910785914603321
996   $aEnvisioning a transformed clinical trials enterprise in the United States$93782380
997   $aUNINA